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Introduction: The aim of this study was to evaluate the safety, pharmacokinetics, and clinical response of brodalumab
(AMG 827), a human, anti-IL-17 receptor A (IL-17RA) monoclonal antibody in subjects with moderate-to-severe
rheumatoid arthritis (RA).
Methods: This phase Ib, randomized, placebo-controlled, double-blind multiple ascending dose study enrolled subjects
with moderate to severe RA (≥6/66 swollen and ≥8/68 tender joints). Subjects were randomized 3:1 to receive
brodalumab (50 mg, 140 mg, or 210 mg subcutaneously every two weeks for 6 doses per group; or 420 mg or 700 mg
intravenously every 4 weeks for two doses per group) or placebo. Endpoints included incidence of adverse events (AEs)
and pharmacokinetics. Exploratory endpoints included pharmacodynamics, and improvements in RA clinical metrics.
Results: Forty subjects were randomized to investigational product; one subject discontinued due to worsening of
RA (placebo). The study was not designed to assess efficacy. AEs were reported by 70% (7/10) of placebo subjects
and 77% (22/30) of brodalumab subjects. Three serious AEs were reported in two subjects; there were no
opportunistic infections. Brodalumab treatment resulted in inhibition of IL-17 receptor signaling and receptor
occupancy on circulating leukocytes. No treatment effects were observed with individual measures of RA disease
activity. On day 85 (week 13) 37% (11/30) of brodalumab subjects and 22% (2/9) of placebo subjects achieved
ACR20; 7% (2/30) brodalumab subjects and 11% (1/9) of placebo subjects achieved ACR50; and 0% (0/30) brodalumab
subjects and 0% (0/9) of placebo subjects achieved ACR70.
Conclusions: Multiple dose administration of brodalumab was tolerated in subjects with active RA. There was no
evidence of a clinical response to brodalumab in subjects with RA.
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Rheumatoid arthritis (RA) is an autoimmune disease
which produces synovitis in diarthrodial joints and is
characterized by the presence of autoreactive T and B
cells and the production of proinflammatory cytokines,
leading to cartilage and bone damage [1]. RA occurs in
approximately 1% of adults of all races worldwide [1].
Conventional treatment with disease-modifying anti-
rheumatic drugs (DMARDs) has been augmented by the
introduction of targeted biologics that specifically inhibit
proinflammatory cytokines [2,3]. Despite the ability of
these therapies to effectively suppress disease activity,
only a minority of patients achieve adequate disease con-
trol (American College of Rheumatology 50% improve-
ment criteria (ACR50)) or disease remission (Disease
Activity Score in 28 joints (DAS28) less than 2.6) [1].
Thus there remains an unmet need for patients with RA
that warrants the development of drugs for treatment
that target new mechanisms of action.
T helper 17 (Th17) cells, a subset of CD4+ effector T
helper cells distinct from the classic Th1 and Th2 lineages,
provide innate and adaptive immunity against pathogens
by orchestrating inflammation signaling through the in-
duction of cytokine, chemokine and matrix metallopro-
tease expression [4]. The downstream effects of Th17 cells
are driven by production of the interleukin 17 (IL-17)
family of cytokines, most notably IL-17A and IL-17 F [5].
Aberrant Th17 responses and IL-17 production have been
implicated in a variety of human autoimmune diseases,
including psoriasis, RA, psoriatic arthritis (PsA) and
multiple sclerosis [6,7].
The role of IL-17 in the pathogenesis of RA has been
studied in both preclinical and clinical studies [5]. In-
creased levels of IL-17A have been detected in the syn-
ovial fluid of patients with RA [8-10], and blockade of
IL-17A signaling can inhibit osteoclast formation in-
duced by conditioned culture media of RA synovial tis-
sues. Furthermore, children with juvenile inflammatory
arthritis (JIA) have elevated IL-17A-positive T cells in in-
flamed joints [11]. In an ex vivo model using explanted
synovial tissue from human RA patients, blockade of
IL-17A reduced the spontaneous production of IL-6 and
collagen breakdown products [12]. Results from early-
phase studies of RA suggest clinical benefits of IL-17A
blockade in RA patients [13,14].
Brodalumab is a human immunoglobulin G2 (IgG2)
monoclonal antibody that binds with high affinity to hu-
man IL-17 receptor A (IL-17RA) and blocks the biological
activity of IL-17A, IL-17 F and IL17-A/F heterodimer sig-
naling through the IL-17RA/RC complex, as well as IL-25
(IL-17E) signaling through the IL-17RA/RB complex. Bro-
dalumab has been shown to be capable of inhibiting the
inflammatory process in psoriasis [7]. In this phase Ib,
randomized, placebo-controlled, double-blind, multipleascending dose study, we evaluated the safety, pharmaco-
kinetics and early clinical response of brodalumab in
patients with moderate to severe RA.
Methods
Participants
Men and women ages 18 to 70 years were eligible for
participation in the study if they had had active RA as
defined by American College of Rheumatology (ACR)
criteria [15] for at least 6 months prior to screening, des-
pite treatment with methotrexate (MTX) consecutively
for 12 weeks or longer. Active RA was defined as six or
more swollen joints; eight or more tender and/or painful
joints; and any one or more of the characteristics eryth-
rocyte sedimentation rate (ESR) 28 mm/h or higher,
C-reactive protein (CRP) above 15 mg/L or morning stiff-
ness for more than 45 minutes. Patients were required to
be on a stable dose of oral or subcutaneous MTX (15 to
25 mg weekly) for at least 4 weeks. Patients currently
taking nonsteroidal anti-inflammatory drugs (NSAIDs) or
oral corticosteroids (not to exceed the equivalent of
10 mg/day prednisone) were required to be on a stable dose
more than 4 weeks prior to screening and to remain on
that stable dose during the treatment period of the study.
Patients who were given any commercial biologic
DMARD within the 3 months prior to enrollment or ri-
tuximab within the 12 months prior to enrollment were
excluded from participation in the study. Patients with evi-
dence of any active, recurrent or recent infections or a his-
tory of malignancy or other autoimmune or uncontrolled
systemic disease were also excluded. Patients with class IV
RA [15], Felty’s syndrome or chronic pain syndrome
requiring daily narcotic analgesics were excluded as well.
This study was approved by the medical ethics com-
mittee of all participating institutions and was per-
formed according to the Declaration of Helsinki. All
participants provided written informed consent prior to
study enrollment.
Study design
This study was a multicenter, randomized, double-blind,
placebo-controlled, multiple ascending dose study in pa-
tients with RA conducted at 11 sites: 7 in the United
States, 2 in Canada and 2 in Mexico. Patients were ran-
domized 3:1 to receive ascending doses of brodalumab
or placebo subcutaneously (cohorts 1 to 3) or intraven-
ously (cohorts 5 and 6). Patients in cohorts 1 to 3 re-
ceived brodalumab (50, 140 or 210 mg) subcutaneously
every 2 weeks for a total of six doses, and those in co-
horts 5 and 6 received brodalumab (420 or 700 mg) by
intravenous (IV) infusion every 4 weeks for a total of
two doses. Cohort 4 was designed to be used in a dose
expansion study to provide evidence of biological impact
in 70 patients with RA receiving a dose of brodalumab
Martin et al. Arthritis Research & Therapy 2013, 15:R164 Page 3 of 9
http://arthritis-research.com/content/15/5/R164defined during the dose escalation phase of the study.
This cohort was not enrolled, because experimental end-
points would be achieved during a separate phase II
study. The dose levels of brodalumab administered in
the study were determined on the basis of the results of
a previous clinical study [7].
Dose escalations required acceptable safety data based
on blinded review of safety data at a dose-level review
meeting following completion of the day 15/week 3 visit
by the final patient in each cohort and when six or more
patients in a cohort had been administered at least three
doses of brodalumab (cohorts 1, 2, 3 and 5). In cohort 6,
dose escalation followed completion of the day 15/week
3 visit by the final patient in cohort 5 and six or more
patients in cohort 5 had been administered two or more
IV infusions of brodalumab. All study personnel remained
blinded to treatment until study completion.
Safety and clinical assessments
Safety was assessed by monitoring adverse events (AEs),
serious adverse events (SAEs) and routine hematologic
and laboratory values for all patients who received at least
one dose of the investigational product (n = 40). RA dis-
ease assessments were completed during a screening visit
and on day −1, 15, 29, 57 and 85 post–brodalumab admin-
istration. RA disease activity was assessed by scoring the
number of swollen joints (n = 66) and tender joints (n = 68),
by Disease Activity Score in 28 joints (DAS28) and by phy-
sician assessment of disease activity. All joint assessments
were performed by an experienced, independent, blinded
joint evaluator. The evaluator could not be the treating
physician and could not interact with the patient through-
out the study beyond the assessment of joints or for any
other patient assessments or laboratory measures of effi-
cacy. In addition to the DAS28, each patient completed a
set of RA disease assessment questionnaires. These patient
questionnaires included patient assessment of disease acti-
vity, patient assessment of pain, patient assessment of phy-
sical function and patient assessment of morning stiffness.
Pharmacokinetics
Serum brodalumab concentration was quantified with a
validated ELISA using a mouse anti-brodalumab mono-
clonal capture antibody (internal clone; Amgen, Thousand
Oaks, CA, USA) and a horseradish peroxidase–conjugated
mouse anti-brodalumab monoclonal detection antibody
(internal clone; Amgen). The ELISA was developed with
tetramethylbenzidine peroxide substrate solution (BioFX
Laboratories, Owings Mills, MD, USA), and optical den-
sity signal was measured at 450 nm.
Pharmacodynamics
IL-17 receptor occupancy (RO) was measured as relative
brodalumab-bound receptors to total available receptorsusing flow cytometry (FACSCalibur; BD Biosciences, San
Jose, CA, USA). Whole blood was stained with CD45
allophycocyanin and CD4 peridinin chlorophyll in com-
bination with either a 1:1 brodalumab:phycoerythrin
(PE) conjugate to report total available receptor, a 1:1 PE
anti-mouse IL-17RA antibody (M204, internal clone;
Amgen) conjugate to report total receptor expression
level, or a human anti-keyhole limpet hemocyanin/anti-
PE isotype control antibody. Heparinized blood samples
were collected, and RO values were determined.
Functional baseline IL-17R signaling in the presence
and absence of drug was examined by measuring IL-6
mRNA induction following a 4-hour exposure to TNF
and a dose titration of IL-17. The IL-6 transcript was
measured using a branched DNA signal amplification
assay of cell lysates from whole blood collected prior to
drug administration. The magnitude of IL-6 mRNA in-
ductions and change in half-maximal effective concen-
tration (EC50) values were calculated for brodalumab
blockade in comparison to predose values.
Immunogenicity assays
Serum samples were tested in an internally validated im-
munoassay (Amgen analytical method) for the presence
of anti-brodalumab-binding antibodies. Equal concentra-
tions of biotinylated and ruthenylated brodalumab in
1 M Tris, pH 9.5, were added to acid-treated patient
serum samples. Following incubation at ambient tem-
perature, samples were transferred to an avidin-coated
MSD high bind plate (Meso Scale Discovery, Rockville,
MD, USA). Plate wells were washed, MSD read buffer
containing tripropylamine was added and the plate was
read on the SECTOR Imager 6000 plate reader (Meso
Scale Discovery). Ruthenylated brodalumab produced
enhanced chemiluminescence signals proportionate to
the concentration of anti-brodalumab antibodies in the
sample. Samples found to be positive for brodalumab-
binding antibodies were further tested using an intern-
ally validated, cell-based bioassay to determine if the
antibodies were able to neutralize the activity of broda-
lumab. Human foreskin fibroblast cells were cultured in
the presence of 5% patient serum and 75 ng/ml brodalu-
mab for 2 hours prior to overnight incubation with
10 ng/ml recombinant human IL-17, which induces se-
cretion of IL-8. The DELFIA TRF (dissociation-enhanced
lanthanide fluorescent immunoassay with time-resolved
fluorescence) assay platform (PerkinElmer, Waltham,
MA, USA) was used to quantify secreted IL-8.
Statistical methods
Demographic, safety, pharmacokinetic, pharmacodynamic
and biomarker data were summarized descriptively by
dose cohort. Descriptive statistics on continuous data in-
cluded means, medians, standard deviations and ranges,
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counts and percentages. As the primary endpoint for this
study was safety/tolerability, no statistical powering was
performed and the sample size was based on feasibility
and historical approaches used for similar studies in this
population. Analyses of safety endpoints were performed
on all patients who were randomized and received at least
one dose of the investigational product.Results
Patient characteristics
All 40 patients enrolled in the study received at least
one dose of investigational product, and 39 completed
the study. One patient received IV placebo and was dis-
continued from study participation on day 85 because of
increased disease activity that warranted systemic inter-
vention. The demographics and baseline characteristics
were generally similar among cohorts (Table 1). The ma-
jority of patients were women (85%) and white (45%) or
Latino (48%). Their mean age was 51.4 years. Disease ac-
tivity at baseline, including swollen and tender joints, pa-




(N = 6) (N = 4) (N =10)
Females, n (%) 5 (83) 4 (100) 9 (90)
Race, n (%)
White 4 (67) 2 (50) 6 (60)
Black 1 (17) 1 (25) 2 (20)
Latino 1 (17) 1 (25) 2 (20)
Asian 0 (0) 0 (0) 0 (0)
Age (yr) 52 (10) 56 (12) 53 (10)
Height (cm) 162 (8) 163 (5) 163 (7)
Weight (kg) 75 (10) 101 (28) 85 (22)
BMI (kg/m2) 29 (4) 37 (9) 32 (7)
Tender/painful joint counts 24 (12) 30 (21) 26 (15)
Swollen joint counts 15 (15) 19 (8) 17 (12)
Patient global assessment of disease activity 72 (23) 57 (22) 67 (23)
Physician global assessment of disease activity 7.7 (1.8) 6.0 (1.8) 7.0 (1.9)
Patient global assessment of pain 72 (23) 63 (18) 68 (20)
HAQ-DI 1.4 (0.9) 1.4 (0.5) 1.4 (0.7)
CRP (mg/L) 15 (17) 26 (39) 19 (26)
ESR (mm/h) 27 (23) 39 (29) 32 (26)
RF-positive, n (%) 4 (67) 4 (100) 8 (80)
aBMI, body mass index; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate
RF, rheumatoid factor; SC, subcutaneous. All data are means (SD) unless otherwise iand measures of systemic inflammation (ESR and CRP)
were generally similar across the cohorts (Table 1).Safety
AEs were reported by seven (70%) of ten patients admin-
istered placebo and by twenty-two (77%) of thirty pa-
tients administered brodalumab (Table 2). The most
common AEs were headache (30%) and cough (13%),
which both occurred more frequently in the placebo
group (40% vs 27% and 20% vs 10%, respectively) than
in the active treatment group.
During the study, three SAEs were reported: compli-
cated migraine in one patient (IV placebo group) and
gastroesophageal reflux disease and noncardiac chest
pain in another patient (in the brodalumab 420 mg IV
group). None of the SAEs were considered by the inves-
tigator to be related to the investigational product. The
investigational product was discontinued in one patient
in the 700 mg IV brodalumab group following the first
of two planned doses because of an AE of oropharyn-
geal candidiasis that was considered by the investigator
not to be drug-related. One patient in the IV placeboBrodalumab
SC IV
50 mg 140 mg 210 mg 420 mg 700 mg All Total
(N = 6) (N = 6) (N = 6) (N = 6) (N = 6) (N = 30) (N = 40)
6 (100) 6 (100) 5 (83) 5 (83) 3 (50) 25 (83) 34 (85)
3 (50) 2 (33) 1 (17) 5 (83) 1 (17) 12 (40) 18 (45)
0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 2 (5)
3 (50) 4 (67) 4 (67) 1 (17) 5 (83) 17 (57) 19 (48)
0 (0) 0 (0) 1 (17) 0 (0) 0 (0) 1 (3) 1 (3)
46 (12) 57 (9) 46 (10) 56 (7) 50 (6) 51 (10) 51 (10)
159 (13) 158 (8) 158 (13) 168 (6) 161 (10) 161 (11) 161 (10)
80 (17) 77 (12) 64 (11) 81 (12) 79 (14) 76 (14) 79 (17)
33 (14) 31 (3) 26 (3) 29 (4) 31 (4) 30 (7) 30 (7)
23 (12) 40 (26) 32 (27) 42 (21) 32 (12) 34 (21) 32 (20)
10 (6) 22 (13) 20 (7) 19 (11) 21 (16) 18 (11) 18 (11)
57 (16) 68 (23) 51 (25) 44 (18) 54 (23) 55 (21) 57 (22)
6.7 (2.1) 6.3 (2.2) 7.3 (2.0) 6.8 (1.9) 7.0 (0.9) 6.8 (1.8) 6.9 (1.8)
60 (18) 71 (17) 49 (28) 49 (14) 60 (24) 58 (21) 60 (21)
1.3 (0.7) 1.7 (0.6) 1.7 (1.0) 1.5 (0.7) 1.7 (0.5) 1.6 (0.7) 1.5 (0.7)
7 (9) 7 (4) 28 (39) 24 (50) 33 (53) 20 (36) 20 (34)
19 (11) 16 (11) 23 (15) 23 (28) 41 (45) 24 (26) 26 (25)
5 (83) 4 (67) 5 (83) 5 (83) 5 (83) 24 (80) 32 (80)
; HAQ-DI, Health Assessment Questionnaire Disability Index; IV, intravenous;
ndicated.
Table 2 Adverse eventsa
Brodalumab
Placebo SC IV
Adverse events SC IV All 50 mg 140 mg 210 mg 420 mg 700 mg All Total
(N = 6) (N = 4) (N =10) (N = 6) (N = 6) (N = 6) (N = 6) (N = 6) (N = 30) (N = 40)
Adverse events, n (%)
Any 3 (50) 4 (100) 7 (70) 5 (83) 5 (83) 4 (67) 5 (83) 4 (67) 23 (77) 30 (75)
Seriousb 0 (0) 1 (25) 1 (10) 0 (0) 0 (0) 0 (0) 1 (17) 0 (0) 1 (4) 2 (5)
Fatal 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Leading to study discontinuation 0 (0) 1 (25) 1 (10) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (3)
Leading to IP discontinuation 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (17) 0 (0) 0 (0)
Common adverse eventsc
Headache 2 (33) 2 (50) 4 (40) 1 (17) 1 (17) 2 (33) 2 (33) 2 (33) 8 (27) 12 (30)
Cough 2 (33) 0 (0) 2 (20) 1 (17) 0 (0) 0 (0) 1 (17) 0 (0) 3 (10) 5 (13)
Abdominal pain 0 (0) 0 (0) 0 (0) 0 (0) 2 (33) 1 (17) 1 (17) 1 (17) 4 (13) 4 (10)
Constipation 1 (17) 1 (25) 2 (20) 0 (0) 0 (0) 2 (33) 0 (0) 0 (0) 2 (7) 4 (10)
Diarrhea 0 (0) 0 (0) 0 (0) 0 (0) 2 (33) 2 (33) 0 (0) 0 (0) 4 (13) 4 (10)
Upper respiratory tract infection 0 (0) 1 (25) 1 (10) 1 (17) 1 (17) 0 (0) 0 (0) 1 (17) 3 (10) 4 (10)
Rash 0 (0) 1 (0) 1 (10) 0 (0) 2 (33) 0 (0) 0 (0) 0 (0) 2 (7) 3 (8)
aIP investigational product; IV, intravenous; SC subcutaneous. bA serious adverse event was defined as an event that was fatal or life-threatening, either required or
prolonged hospitalization or caused persistent or substantial disability or incapacity or congenital anomaly or birth defect or an event that was considered by the
investigator to be a medically important event. cCommon adverse events were those that were reported in at least three patients from all brodalumab-treated
groups combined.
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flare.
The frequency of treatment-related infections was low
(7.5%), with no treatment-related infections reported in
more than one patient, one case of cellulitis (placebo),
one case of herpes zoster (brodalumab 420 mg IV group)
and one upper respiratory tract infection (brodalumab
140 mg SC group). No deaths occurred during the study.
One patient (brodalumab 50 mg SC) experienced transi-
ent decreased neutrophil counts (nadir 1.47 × 103/μl on
day 106), which normalized spontaneously by day 127
without an interruption of or decreased dosing, no
symptom development or no administration of bone
marrow–stimulating agents.
Serological evaluation for anti-human antibodies
Two (6.7%) of the brodalumab-treated patients tested
positive for anti-brodalumab-binding antibodies, with
both positives observed only on day 127. Both binding
antibody samples tested negative for the presence of
neutralizing anti-brodalumab antibodies. None of the
placebo-treated patients tested positive for the presence
of anti-brodalumab-binding antibodies.
Pharmacokinetic analysis
Brodalumab exhibited nonlinear pharmacokinetics in pa-
tients with RA. Following a single dose or multiple SCdoses of brodalumab across a dose range of 50 to
210 mg, the maximum serum concentration (Cmax) and
the area under the serum concentration time curve
(AUC0-t) increased greater than dose proportionally
(Table 3 and Figure 1). Accumulation, measured as the
ratio of AUC0-t following the final dose/AUC0-t following
the first dose, was less than twofold following multiple-
dose SC (140 or 210 mg) or IV (420 or 700 mg) adminis-
tration of brodalumab (Figure 1). The median time to
Cmax (tmax) was approximately 2 to 4 days following ei-
ther a single SC dose or six SC doses of brodalumab at
50, 140 or 210 mg brodalumab (Figure 1).
Pharmacodynamic measures following administration
of brodalumab
Mean IL-17 RO on circulating leukocytes in whole blood
from placebo patients was minimal (less than 3%) at all
time points. Treatment with brodalumab resulted in
dose-dependent increases in IL-17 RO on circulating
leukocytes, with mean IL-17 RO increases greater than
95% on day 3 for all dose levels (data not shown). The
mean (SD) predose trough levels on days 15, 43 and 85
in the 50 mg, 140 mg and 210 mg brodalumab groups
were 34.6% (4.0), 91.3% (2.9) and 97.2% (0.2), respect-
ively. IL-17 RO in the brodalumab IV groups (420 mg
and 700 mg) was 99% on day 3 and predose trough
levels were generally above 90% on day 29 for both IV
Table 3 Mean pharmacokinetic parameter estimate of brodalumab following multiple subcutaneous and intravenous
doses given to rheumatoid arthritis patientsa
Predicted human exposure after multiple SC (n = 6)
or IV (n = 2) doses
Exposure margin based on exposure in monkeys after 3-month
weekly SC doses or 1-month weekly IV dosesb
Dose (mg) AUC0-t
c (μg/h/ml) Cmax (μg/ml) AUC (μg/h/ml) Cmax (μg/ml)
50 (SC) 71.3 0.947 4,458 1,246
140 (SC) 2170 9.05 146 130
210 (SC) 6610 23.2 48 51
420 (IV) 24,800 113 126 89
700 (IV) 48,600 198 64 51
aAUC, area under the curve; AUC0-t, area under the serum concentration time curve; Cmax, maximum serum concentration; IV, intravenous; SC, subcutaneous.
bNo adverse effect level for monkeys is 90 mg/kg SC or 350 mg/kg IV. AUC0-168 hours and Cmax after the 12th dose of 90 mg/kg weekly SC were 159,000 μg/h/ml
and 1,180 μg/ml, respectively. AUC0-168 hours and Cmax after fourth dose of 350 mg/kg weekly IV were 782 000 μg/h/ml and 10,100 μg/ml, respectively.
cAUC0-t = AUC0-336 hours for SC cohorts and AUC0-672 hours for IV cohorts.
Time (days)






















































Cohort 5 (420 mg IV)
Cohort 6 (700 mg IV)
A
B
Cohort 1 (50 mg SC)
Cohort 2 (140 mg SC)
Cohort 3 (210 mg SC)
Figure 1 Mean (SD) serum brodalumab concentration × time profiles (semilog) in rheumatoid arthritis patients following (A) repeat
subcutaneous administration and (B) repeat intravenous administration. IV, intravenous; SC, subcutaneous.
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drug was measurable. When brodalumab concentrations
were above the lower limit of quantification, occupancy
92% or higher was observed at all but two time points
(Figure 2). At one time point, the brodalumab serum
concentration was very low (0.056 μg/ml). These data
demonstrate the limits of the ability to measure un-
bound (that is, free) brodalumab in circulation, given the
high levels of target on circulating cells and the high
affinity of brodalumab for IL-17RA. These data de-
monstrate effective binding of the antibody to target
throughout the periods of measured exposure.
To investigate a functional biological effect of brodalu-
mab on modulating baseline IL-17R signaling, an ex vivo
assay measured changes in the expression of IL-6 mRNA
pre- and postdose with brodalumab in the presence of
increasing levels of exogenously added IL-17. In patients
with a strong IL-6 mRNA response, competitive inhib-
ition of IL-17R signaling caused an increase in EC50
(concentration of IL-17 causing a 50% increase in IL-6
mRNA) after brodalumab administration, with minimal
changes in magnitude of the IL-6 response. However,
the magnitude of the IL-6 response was attenuated in
many RA patients before brodalumab administration,
with a lower magnitude of IL-6 mRNA production com-
pared to healthy volunteers or psoriasis patients [16]. As
a result, accurate measurements of changes in EC50 was
not possible in all patients, and pre- and postdose sam-
ples from RA patients were investigated for potential
normalization of reduced magnitude of IL-6 response on























Figure 2 Relationship between interleukin 17 receptor
occupancy levels and serum brodalumab concentrations. Each
symbol represents an individual sample collected during the study
for all patients receiving brodalumab. Circles indicate samples with
detectable pharmacokinetic (PK) levels of serum brodalumab, and
triangles indicate samples below the level of quantitation (LOQ).predose samples from several patients displayed the at-
tenuated IL-6 mRNA response, no significant increase in
the magnitude of the IL-6 mRNA response was observed
following treatment with brodalumab compared to pla-
cebo (data not shown).
Clinical responses to brodalumab
On day 85 (week 13), ACR20 had been achieved by 11
(37%) of 30 of patients receiving brodalumab and 2
(22%) of 9 of patients receiving placebo (Table 4).
ACR50 scores were observed in one of nine and two of
thirty placebo and brodalumab patients, respectively, on
day 85. At day 85 (week 13), mean (SD) DAS28 scores
were 4.76 (1.41) and 4.39 (1.13) in the brodalumab and
placebo groups, respectively. These data represent mod-
est decreases from baseline values of 5.58 (1.26) and
5.54 (1.20), respectively, with a maximum mean change
throughout the study of −0.81 (0.86) at day 85 (week 13)
for brodalumab patients and −1.34 (0.90) at day 57 for
placebo patients (data not shown).
Discussion
IL-17 is an innate proinflammatory cytokine that has
been shown to contribute to psoriasis pathogenesis [7]
and a subset of additional inflammatory diseases, includ-
ing RA and PsA [13,14] but not Crohn’s disease [17].
Signaling through the IL-17R complex (IL-17RA:IL-
17RC for IL-17A, IL-17 F and IL-17A/F) by various IL-
17 ligands promotes host defense through effects on
neutrophil homeostasis and the elaboration of proin-
flammatory factors, including cytokines, chemokines and
antimicrobial peptides. The primary goal of this study
was to assess the safety, tolerability, pharmacokinetics
and immunogenicity of multiple doses of brodalumab in
patients with RA. The planned dose expansion portion
of this study, which included a primary efficacy endpoint
in RA, was not performed. Instead, a separate phase II
multiple-dose study was conducted to evaluate the effi-
cacy of brodalumab in patients with RA.
Analysis of the safety data showed an acceptable safety
profile for brodalumab. Three SAEs, none of which were
considered related to the investigational product, were
reported in two patients. One patient (placebo IV) was
discontinued from the study early because of an RA
flare. There was no evidence of a significant increase in
infectious AEs in patients receiving brodalumab. No
deaths, dose-limiting toxicities or neutralizing anti-
brodalumab antibodies were reported. The incidence of
treatment-emergent AEs was similar between the broda-
lumab and placebo groups. No clinically significant ab-
normalities in electrocardiograms, safety laboratory
values or vital signs were reported. These findings are
consistent with the overall safety profile of brodalumab
in larger studies of patients with psoriasis [7].
Table 4 ACR20/50/70 responses for patients receiving brodalumab or placeboa
Brodalumab
Placebo SC IV
Response, n/N (%) SC IV All 50 mg 140 mg 210 mg 420 mg 700 mg All Total
(N = 6) (N = 4) (N = 10) (N = 6) (N = 6) (N = 6) (N = 6) (N = 6) (N = 30) (N = 40)
ACR20 Day15 2/5 (40) 1/4 (25) 3/9 (33) 0/5 (0) 0/6 (0) 1/6 (17) 3/6 (50) 3/6 (50) 7/29 (24) 10/38 (26)
Day 29 1/4 (25) 2/4 (50) 3/8 (38) 2/6 (33) 2/6 (33) 0/6 (0) 3/6 (50) 2/6 (33) 9/30 (30) 12/38 (32)
Day 57 3/5 (60) 2/4 (50) 5/9 (56) 1/6 (17) 0/6 (0) 1/6 (17) 3/6 (50) 4/5 (80) 9/29 (31) 14/38 (37)
Day 85 2/6 (33) 0/3 (0) 2/9 (22) 2/6 (33) 2/6 (33) 1/6 (17) 2/6 (33) 4/6 (67) 11/30 (37) 13/39 (33)
ACR50 Day15 0/6 (0) 0/4 (0) 0/10 (0) 0/5 (0) 0/6 (0) 0/6 (0) 0/6 (0) 1/6 (17) 1/29 (3) 1/39 (3)
Day 29 1/5 (20) 0/4 (0) 1/9 (11) 0/6 (0) 0/6 (0) 0/6 (0) 1/6 (17) 0/6 (0) 1/29 (3) 2/39 (5)
Day 57 1/6 (17) 0/4 (0) 1/10 (10) 0/6 (0) 0/6 (0) 0/6 (0) 0/6 (0) 0/6 (0) 0/30 (0) 1/40 (3)
Day 85 1/6 (17) 0/3 (0) 1/9 (11) 1/6 (17) 1/6 (17) 0/6 (0) 0/6 (0) 0/6 (0) 2/30 (7) 3/39 (8)
ACR70 Day15 0/6 (0) 0/4 (0) 0/10 (0) 0/5 (0) 0/6 (0) 0/6 (0) 0/6 (0) 0/6 (0) 0/29 (0) 0/39 (0)
Day 29 0/6 (0) 0/4 (0) 0/10 (0) 0/6 (0) 0/6 (0) 0/6 (0) 0/6 (0) 0/6 (0) 0/30 (0) 0/40 (0)
Day 57 1/6 (17) 0/4 (0) 1/10 (10) 0/6 (0) 0/6 (0) 0/6 (0) 0/6 (0) 0/6 (0) 0/30 (0) 1/40 (3)
Day 85 0/6 (0) 0/3 (0) 0/9 (0) 0/6 (0) 0/6 (0) 0/6 (0) 0/6 (0) 0/6 (0) 0/30 (0) 0/39 (0)
aACR20, 20% American College of Rheumatology improvement criteria; ACR50, 50% American College of Rheumatology improvement criteria; ACR70, 70% American
College of Rheumatology improvement criteria; IV intravenous, SC subcutaneous. All data are mean (SD) unless otherwise indicated.
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patients with RA after SC administration within a dose
range of 50 to 210 mg. Serum brodalumab exposure, as
measured by Cmax and AUC0-t, increased more than
dose-proportionally across the dose range of 50 to
210 mg after single or multiple SC doses of brodalumab
given to RA patients. Treatment with brodalumab re-
sulted in dose-dependent increases in IL-17 RO on cir-
culating leukocytes and clear evidence of prolongation of
the duration of greater than 90% RO by brodalumab. RO
greater than 90% in the presence of any measurable bro-
dalumab, along with numerous RO measurements de-
monstrating significant target coverage in the absence of
measurable brodalumab, indicate that some IL-17R
coverage on circulating leukocytes is sustained following
the disappearance of measurable concentrations of bro-
dalumab. However, the functional effect of this low-level
coverage is unknown and may be minimal. Moderate
concentrations of IL-17 ligand would be expected to be
able to displace brodalumab at these levels.
Exploratory efficacy analyses, including widely used com-
posite indices of signs and symptoms of RA (ACR20 and
DAS28), did not reveal any clinical responses to brodalumab
in patients with RA. Twelve weeks after study initiation,
15% of patients receiving brodalumab and 7.5% of patients
given placebo achieved ACR50 responses. The single
ACR70 response in this study was observed in a placebo pa-
tient. Individual ACR components also failed to show a dif-
ference between placebo- and brodalumab-treated patients.
This small efficacy data set does not provide confidence that
inhibition of IL-17R with brodalumab at doses up to210 mg SC every other week or 700 mg IV monthly is likely
to have significant impact on short-term clinical outcomes
in RA. The mechanism of this nonresponse and differences
from clinical responses observed in other diseases is un-
known. Potential explanations for the lack of response in-
clude insufficient power to detect modest improvements in
this small study and mechanisms that may be specific to
blockade of IL-17RA. Receptor blockade could affect mul-
tiple ligands (including IL-25) with unknown functions in
RA or may require higher levels of target coverage in the
synovium. Notably brodalumab has shown evidence of a
clinical effect in psoriasis following single and multiple
administrations at the same dose level as that used in this
RA study [7,18]. Clinical studies powered to assess the cli-
nical efficacy of brodalumab in both MTX-resistant RA and
PsA have been completed (Trial registrations: Clinicaltrials.
gov NCT00950989 and NCT01516957) [19]. These phase II
data will enable a more thorough comparison of the efficacy
response observed with brodalumab with therapeutics tar-
geting IL-17A, particularly in RA cases where responses
have been mixed and equivocal [20,21].
Conclusion
In this small, ascending-dose, phase Ib study, we have
demonstrated that multiple SC and IV doses of brodalu-
mab were tolerated by patients with active RA. Conclu-
sions about the efficacy of brodalumab in RA patients
cannot be reached on the basis of these results, given
the study design, although limited clinical effect and no
clear dose–response relationship was observed in RA
patients receiving brodalumab.
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